Pharmaceutical Industry
Filter News
Found 28,351 articles
-
The U.S. FDA approved Pfizer’s Xalkori (crizotinib) for pediatric patients one year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma that is anaplastic lymphoma kinase (ALK)-positive.
-
As the 2021 virtual JP Morgan Healthcare Conference wrapped up, there was still news from companies regarding their deals, pipeline and regulatory updates. Here’s a look.
-
Although there are now two authorized vaccines against COVID-19 available in the United States and a third likely on the way with Johnson & Johnson’s candidate, the nation and world are nowhere near being done with the novel coronavirus, especially with new, more contagious variants now circulating.
-
BioSpace Movers & Shakers, Jan. 15
1/15/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers and Shakers. -
Nadim Ahmed, president of hematology at BMS, is leaving the company to, according to “pursue other opportunities.”
-
Biopharma companies raking in the cash with investment rounds and IPO announcements.
-
Agenda for Calliditas virtual R&D Day on January 20, 2021
1/15/2021
Calliditas Therapeutics AB announced the program for the upcoming virtual R&D Day for investors, analysts and journalists on January 20, 2021, which will take place between 1pm and 5pm CET.
-
TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications
1/15/2021
Analyses of pivotal study data of Dysport® reveal a large proportion of study patients did not require retreatment for at least 12 weeks
-
The filing to the U.S. District Court District of New Jersey, dated December 31st, 2020, states that the materials include compound data, strategic plans related to translational and biomarker data, therapeutic program reviews, abstract publications, plans for Congressional presentations, drug mo...
-
Like many biopharma companies, the global COVID-19 pandemic has caused delays while also offering opportunities for NeuroRx.
-
On January 4, the company announced slightly murky data from its first-in-patients 12-week Phase II proof-of-concept trial of BT-11 for mild to moderate ulcerative colitis.
-
Here’s a look at some of the stories that emerged from the conference on Wednesday.
-
Billionaire entrepreneur Mark Cuban, best known as the owner of the Dallas Mavericks and an investor on the ABC business reality series “Shark Tank,” is diving into generic drugs with a new startup, dubbed Mark Cuban Cost Plus Drug Company.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
Many buyers are becoming increasingly interested in buying these promising companies before they go public, as this often makes the purchase more economically feasible.
-
Sunshine Biopharma Receives Fourth Tranche From Previously Announced $2,000,000 + Financing for Coronavirus Treatment
1/14/2021
Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announced that it has received the fourth tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc.
-
AcelRx Announces Year-End 2020 Metrics and Review of 2020 Achievements
1/14/2021
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, announced preliminary unaudited financial results and other information in connection with its participation in investor presentations, meetings and events during the week of the 39th Annual J.P. Morgan Healthcare Conference.
-
China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer
1/14/2021
BeiGene, Ltd., a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration for use in combination with two chemotherapy regimens as a first-line treatment for patients with advanced squamous non-small cell lung cancer.
-
NewAmsterdam Pharma Completes $196M (€160M) Series A Funding for Comprehensive Phase 3 Development Program
1/14/2021
Founding investor Forbion joined by co-lead investors, Morningside Ventures and Ascendant BioCapital, and other leaders in global biopharmaceutical investment
-
Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC
1/14/2021
Hutchison China MediTech Limited announces that the final analysis of savolitinib in Phase Ib TATTON study Parts B and D will be presented at the upcoming virtual 2020 World Conference on Lung Cancer, taking place on January 28-31, 2021, virtually.